We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Tapan Panchal
LONDON--AstraZeneca PLC (AZN.LN) said Monday that it has signed an agreement with a unit of rival French pharmaceutical company Sanofi SA (SAN.FR) for the sale of cancer drug Caprelsa for $300 million.
The U.K.-listed pharmaceutical company entered into a definitive pact with Genzyme to divest Caprelsa, which is used for treating thyroid cancer. The medicine is currently available in 28 countries and had sales of $48 million in 2014.
Under the agreement, Genzyme will pay AstraZeneca an upfront payment of $165 million to acquire the global rights to sell and develop Caprelsa, and further development and sales milestone payments of up to $135 million. The transaction doesn't include the transfer of any AstraZeneca employees or facilities.
The sale is expected to complete in the second half of 2015 and doesn't affect AstraZeneca's 2015 earnings guidance.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
